Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07642908 · ClinicalTrials.gov registry record
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
A clinical trial, sponsored by University of Michigan.
- Recruiting
- Registry status
- 15
- Enrollment target
NCT07642908 is a clinical trial that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 15 participants.
The verdict
NCT07642908 is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- 15 participants
- Enrollment target
Study Summary
This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-09-18 |
| Est. Completion | 2026-09-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07642908
The ClinicalTrials.gov registry entry for NCT07642908 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07642908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07642908 about?
NCT07642908 is a clinical study titled "Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation". This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography ...
What is the current status of trial NCT07642908?
This trial is currently recruiting. The enrollment target is 15 participants. The study started on 2025-09-18. Estimated completion is 2026-09-17.
Who is sponsoring clinical trial NCT07642908?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.